Physician profile
David Burstein
NPI 1861462707
$1,962.34
in general payments reported to CMS, 2019-2025
24 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2021: $82.40 · 2022: $256 · 2023: $531 · 2024: $444 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.85 |
| Education | $147.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $414.15 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $277.79 | 2019-2024 | Farxiga |
| Daiichi Sankyo INC. | $263.98 | 2022-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $233.22 | 2022-2025 | |
| Amgen INC. | $164.24 | 2024-2025 | Krystexxa |
| Opko Pharmaceuticals, LLC | $139.17 | 2021-2025 | Rayaldee |
| Vifor Pharma, INC. | $49.99 | 2021-2023 | Veltassa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.56 | 2024-2025 | Jynarque |
| Travere Therapeutics, INC. | $42.08 | 2024-2025 | Filspari |
| Novo Nordisk INC | $34.79 | 2025 | Ozempic |
| Baxter Healthcare | $31.36 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.85 | 2024 | Acthar |
| Akebia Therapeutics INC | $29.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.28 | 2023 | Ultomiris |
| Abbvie INC. | $23.07 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $21.01 | 2025 | Tarpeyo |
| Boston Scientific Corporation | $19.79 | 2023 | |
| Abiomed | $19.69 | 2023 | Impella |
| Aurinia Pharma U.S., INC. | $19.29 | 2022 | |
| Cormedix INC. | $18.96 | 2024 | Defencath |
| Ardelyx, INC. | $18.15 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $17.69 | 2024 | Velphoro |
| Genzyme Corporation | $13.35 | 2019 | |
| Horizon Therapeutics Plc | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Burstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.